Skip to Main Content
Contribute Try STAT+ Today

A pivotal phase 2 clinical trial designed to help Celgene (CELG) and Bluebird Bio (BLUE) secure approval for the first CAR-T therapy targeting multiple myeloma will begin enrolling patients next week.

A listing for the clinical trial of the CAR-T therapy known as BB2121 was posted to the government’s website on Tuesday, with a planned start date of Dec. 11. Celgene licensed BB2121 from Bluebird and is the sponsor of the study, which the company is calling KarMMA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.